OSR1

In mice, during gastrulation on embryological day 7.5, cells fated to become intermediate mesoderm show the mouse OSR1 homologue, Osr1, expression. A day later, it is expressed in the intermediate mesoderm, lateral to the neural plate. Osr1 expression weakens and shifts posteriorly, to the presumptive kidneys, by day 9.5. By day 10.5, the branchial arch and limbs also begin to express Osr1.[12][14]

Mice carrying a targeted null mutation in the Odd1 gene show that Odd1 is essential forheart and intermediate mesoderm development.[15]Osr1 regulates atrial septum formation in the heart. Osr1 is expressed in the dorsal atrial wall, from which the primary atrial septum will emerge, and later in the septum and left venous valve leaflet.[14] It is also present in the mesothelium of the thoracic cavity and the parietal pericardium.[14] Embryos lacking Osr1 expression usually die before birth due to deformed atrioventricular junctions and hypoplastic venous valves; the ones that progress to term also have an incomplete parietal pericardium.[14] These pathologies occur in the presence of other transcription factors important for atrial septum formation such as Nkx2.5, Pitx2 and Tbx5.[14]Deleting Osr1 in second heart field(SHF) demonstrated absence of the atrial septum.It is also demonstrated that Osr1 is a direct downstream target of Tbx5 in the SHF and establish a Tbx5-Osr1 pathway parallel to Hh signaling required for atrial septation.[16] Osr1 can also interact with Tbx5 to regulate posterior second heart field cell cycle progression for cardiac septation.[17]

Osr1 is the earliest marker of the intermediate mesoderm, which will form the gonads and kidneys. This expression is not essential for the formation of intermediate mesoderm but for the differentiation towards renal and gonadal structures.[14][18] Osr1 acts upstream of and causes expression of the transcription factors Lhx1, Pax2 and Wt1 which are involved in early urogenital development.[14] In normal kidney development, activation of the Pax2-Eya1-Hox11 complex and subsequent activation of Six2 and Gdnf expression allows for branching of the ureteric bud and maintenance of the nephron-forming cap mesenchyme.[19] Six2 maintains the self-renewing state of the cap mesenchyme.[20] and Gdnf, via the Gdnf-Ret signalling pathway, is required for attraction and branching of the growing ureteric bud.[21] Within the developing kidney, Osr1 expressing cells will become mesangial cells, pericytes, ureteric smooth muscle and the kidney capsule. The cell types that Osr1 expressing cells will differentiate into are determined by the timing of loss of expression – cells that will become part of the vasculature or ureteric epithelium lose expression of Osr1 early (E8.5), and those that become nephrons lose expression later (E11.5).[22] All three stages of kidney formation are affected in mice lacking Osr1 expression and are similar to mice with reduced Wt1 and Pax2 expression – the Wollfian duct is abnormal, there are fewer mesonephric tubules and the kidney-forming metanephros and gonads are missing.[14] In embryonic day 10.5, embryos lacking Osr1 expression fail to grow a ureteric bud that migrates into the uncompacted metanephric mesenchyme.[14] The lack of inductive signals from the ureteric bud combined with a downstream reduction in Pax2 expression results in apoptosis and agenesis of the kidney.[14]

Expression of Osr1 in the limb buds is initially restricted to the mesenchyme immediately below the endoderm, but shifts anteriorly and proximally by embryonic day 11.5.[12] In mice, Osr1 is expressed in the interdigital mesenchyme[12] and presumptive synovial joints during limb development.[23] where it overlaps with expression of Gdf5, an early marker for joint formation.[24] Mouse embryonic limb muscle connective tissue(MCT) cells express the transcription factor Osr1, differentiating into fibrogenic and adipogenic cells in vivo and in vitro and defining an embryonic Fibro-adipogenic progenitors (FAP) like population. Genetic lineage tracing shows that developmental Osr1+ cells give rise to a subset of adult FAPs. Loss of Osr1 function leads to a reduction of myogenic progenitor proliferation and survival resulting in limb muscle patterning defects.[25]

The expression of OSR1 is more reduced in lung cancer tissues than in normal lung tissues, and was correlated with poor differentiation. OSR1 could downregulat the activity of the Wnt signaling pathway by suppressing the expression of SOX9 and β‐catenin.[26] OSR1 expression is also significantly down-regulated at both mRNA and protein levels in primary gastric cancer tissues compared with adjacent normal tissues.It acts as a functional tumour suppressor through the transcriptional activation of p53 and repression of TCF/LEF in gastric cancer.[27] OSR1 expression was downregulated in primary RCC and negatively correlated with histological grade. Downregulation of OSR1 might represent a potentially prognostic marker and therapeutic target for RCC.

Osr1 is expressed in the first and second branchial arches, in the limb buds, mouth and nasal pits, in the trunk, the forebrain.,[12] developing somites, distal mandible and developing eye.[13]

A variant human OSR1 allele which does not produce a functional transcript and found in 6% of Caucasian populations, reduces the size of the newborn kidney by 11.8%.[30]

OSR1 is methylated and downregulated in 51.8% of gastric cancer cells and tissues.[31] When expressed normally, OSR1 is anti-proliferative – it induces cell cycle arrest and induces apoptosis in gastric cancer cell.[31] OSR1 is methylated in above 85% of squamous cell carcinomas.[32]>